MS. JANE REINOSO PA-C
Prescription History 1366499642
Physician Assistant - Medical in Ellsworth, ME

NPI Status: Active since May 30, 2006

Contact Information

235 HIGH ST
ELLSWORTH, ME
ZIP 04605
Phone: (207) 412-5200

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. JANE REINOSO PA-C, an active Medical specialist practicing in Ellsworth, ME. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 107 documented patient claims. Among these therapy options, the most frequently utilized medication is Amoxicillin-Clavulanate Potass, which accounts for 31 claims alone.


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 310
ME State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply169
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 72.2% higher than the standard regional baseline profile for ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $536.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.31

State Avg Cost Per Claim

$16.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 80
ME State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply273
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $105.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.62

State Avg Cost Per Claim

$11.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Cephalexin

Generic Formulation: CephalexinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 134
ME State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply274
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $184.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.16

State Avg Cost Per Claim

$9.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Lagevrio (Eua)

Generic Formulation: MolnupiravirSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 65
ME State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.8
Peer Average Days Supply93
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.85

State Avg Cost Per Claim

$10.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with molnupiravir. Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 101
ME State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply193
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.59

State Avg Cost Per Claim

$26.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Prednisone

Generic Formulation: PrednisoneSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 89
ME State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills51.0
Peer Average Days Supply925
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.0% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.13

State Avg Cost Per Claim

$6.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. JANE REINOSO PA-C provides transparency into local medical care patterns within Ellsworth, ME.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.